Dr Louiza S Velentzis

Research Fellow
E: louizav@nswcc.org.au


Dr Velentzis is a cancer epidemiologist and member of the Breast Cancer Group and the Cervical Cancer and HPV Group. She is involved in policy relevant research on cervical and breast cancer prevention with a focus on screening. Key areas of interest include the impact of HPV vaccination, modifiable risk factors for female cancers with a focus on exogenous hormones, risk-based breast cancer screening and the use of modelling in the context of cancer prevention and control.


  • PhD, University College London
  • Master of Science, Imperial College London
  • Postgraduate certificate of Education, University College London
  • Bachelor of Science (joint Honours), Biochemistry and Microbiology, King’s College London

Academic affiliations

  • Honorary Research Fellow, The University of Sydney
  • Honorary Lecturer, The University of Melbourne

Current student supervision

Dr Susan Yuill, PhD candidate, School of Public Health, University of Sydney

Selected key publications

Nickson C, Procopio P, Velentzis LS, et al. Prospective validation of the NCI Breast Cancer Risk Assessment Tool (Gail Model) on 40,000 Australian women. Breast Cancer Res. 2018;20(1):155. Published 2018 Dec 20. doi:10.1186/s13058-018-1084-x

Velentzis LS, Smith MA, Simms KT, et al. Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia. Gynecol Oncol. 2019;152(3):465-471. doi:10.1016/j.ygyno.2018.12.019

Xu H, Egger S, Velentzis LS, et al. Hormonal contraceptive use and smoking as risk factors for high-grade cervical intraepithelial neoplasia in unvaccinated women aged 30-44 years: A case-control study in New South Wales, Australia. Cancer Epidemiol. 2018;55:162-169.

Velentzis LS, Caruana M, Simms KT, et al. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country. Int J Cancer. 2017;141(12):2410-2422. doi:10.1002/ijc.30926

Arriaga ME, Vajdic CM, Canfell K, Robert J MacInnis, Banks E, Byles JE, Magliano DJ, Taylor AW, Mitchell P, Giles GG, Shaw JE, Gill TK, Klaes E, Velentzis LS, Cumming RG, Hirani V, Laaksonen MA. The preventable burden of breast cancers for premenopausal and postmenopausal women in Australia: A pooled cohort study. Int J Cancer. 2019;145(9):2383-2394. doi:10.1002/ijc.32231

Velentzis LS, Banks E, Sitas F, Salagame U, Tan EH, Canfell K. Use of Menopausal Hormone Therapy and Bioidentical Hormone Therapy in Australian Women 50 to 69 Years of Age: Results from a National, Cross-Sectional Study. PLoS One. 2016;11(3):e0146494. Published 2016. doi:10.1371/journal.pone.0146494

Velentzis LS, Keshtgar MR, Woodside JV, et al. Significant changes in dietary intake and supplement use after breast cancer diagnosis in a UK multicentre study. Breast Cancer Res Treat. 2011;128(2):473-482. doi:10.1007/s10549-010-1238-8